Immunotherapy plus chemotherapy for newly diagnosed glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have been recently diagnosed with glioblastoma (a type of brain tumor) and have completed standard treatment (radiation and the chemo drug temozolomide).
- Your daily steroid dose must be low (equivalent to 4 mg of dexamethasone or less).
- You must be in good physical condition (able to care for yourself, with a Karnofsky score of 70% or above).
- You must have adequate organ function, including healthy blood counts and liver and kidney function.
- You cannot have received certain prior treatments, such as immunotherapy, and you cannot have certain medical conditions (like active autoimmune diseases, heart problems, or multifocal tumors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This trial tests a combination of two oral medications (vebreltinib and temozolomide) after surgery for a specific type of brain cancer called glioblastoma. The goal is to see if this combination can help stop the cancer from growing back.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.